Autopsy report · NCT00968799

Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study

“poor patient accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 10 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Cantonal Hospital of St. Gallen

Sponsor type

University, hospital or other

Conditions

Epithelial Ovarian Cancer; Fallopian Tube Carcinoma

Interventions

Hyperthermic intraoperative intraperitoneal chemotherapy; Cytoreduction; Cisplatin

Participants

6

Sites

1

Countries

Switzerland

Trials that died the same way

• Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
  “Inadequate patient accrual” (93% match in meaning)
• Dose-adjusted EPOCH-R in MYC Positive DLBCL
  “Poor accrual of eligible patients” (89% match in meaning)
• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (89% match in meaning)
• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
  “Lack of patient accruals.” (81% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.